APA (7th ed.) Citation

NS, J., AV, W., N, G., & S, S. (2026). Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management. Clinical pharmacology in drug development, 15(3), e1624. https://doi.org/10.1002/cpdd.1624

Chicago Style (17th ed.) Citation

NS, Jayathilaka, Weththasinghe AV, Ganamurali N, and Sabarathinam S. "Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management." Clinical Pharmacology in Drug Development 15, no. 3 (2026): e1624. https://doi.org/10.1002/cpdd.1624.

MLA (9th ed.) Citation

NS, Jayathilaka, et al. "Integrating Pharmacogenomic Insights in GLP-1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management." Clinical Pharmacology in Drug Development, vol. 15, no. 3, 2026, p. e1624, https://doi.org/10.1002/cpdd.1624.